GBT Guerbet SA

Guerbet: Financial agenda for 2024

Guerbet: Financial agenda for 2024

Financial agenda for 2024

Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.

Publications calendar
  • 2023 ANNUAL REVENUE
February 08, 2024, after trading
  • 2023 ANNUAL RESULTS
March 20, 2024, after trading
  • 2024 1ST QUARTER REVENUE
April 25, 2024, after trading
  • ANNUAL SHAREHOLDERS’ MEETING
May 24, 2024
  • 2024 2ND QUARTER REVENUE
July 25, 2024, after trading
  • 2024 FIRST HALF RESULTS
September 25, 2024, after trading
  • 2024 3RD QUARTER REVENUE
October 24, 2024, after trading

 

 

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.

Contacts :

Guerbet     

Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 /

Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 /

Actifin        

Marianne Py, Financial Communication + 33.1.80.48.25.31 /

Jennifer Jullia, Media Relations +33.1.56.88.11.19 /

Attachment



EN
15/01/2024

Underlying

GBTGuerbet SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Guerbet SA

Anthony Dick ... (+2)
  • Anthony Dick
  • Michael Foundoukidis
AMS AMS AG
PROX Proximus SA de ... ... (+39)

ODDO BHF Small & MIDCAP MORNING NEWS - 04/26/2024 Date Performance sin...

Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...

AMS AMS AG
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
04/26/24 April 26, 2024 1 EN
Anthony Dick ... (+2)
  • Anthony Dick
  • Michael Foundoukidis
AMS AMS AG
PROX Proximus SA de ... ... (+39)

ODDO BHF Small & MIDCAP MORNING NEWS - 26/04/2024

Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...

AMS AMS AG
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
04/26/24 April 26, 2024 1 FR
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
GBT GUERBET SA

Guerbet : Q1 2024 revenue: a solid sales performance

>Q1 2024 revenue +8%: solid - Revenue increased by 8.1% in Q1 to € 194.3m (+8.8% cc.) or +7.6% after adjusting the first quarter of 2023 to include Intrasense consolidated since 01/01/2023. The EMEA region posted a decline of 5.8% (-6.2% cc), APAC delivered 20% growth (+26.8% cc) and the Americas recorded 21% growth (+20% cc). The X-ray business turned in +15%, the IRM business -4% and the II business +4.4%.Management confirmed its guidance targets (8% growt...

04/26/24 April 26, 2024 1 EN
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
GBT GUERBET SA

Guerbet : CA T1 2024 : bonne performance commerciale

>CA T1 2024 : +8% : solide - Le CA T1 affiche une hausse de 8,1%, à 194,3 M€ (+8,8% à tcc.) et +7,6% en retraitant le premier trimestre 2023 afin d’intégrer Intrasense, consolidée depuis le 1/1/2023. L’EMEA est en baisse de 5,8% (-6,2% à tcc.), l’APAC progresse de 20% (+26,8% à tcc.) et les Amériques sont en hausse de 21% (+20% à tcc.). Les Rayons-X affichent +15%, l’IRM recule de 4%, et la RIT augmente de 4,4%.Le management a confirmé sa guidance (croissanc...

04/26/24 April 26, 2024 1 FR
 PRESS RELEASE
Free
GBT GUERBET SA

Guerbet : Q1 2024 revenue.

Guerbet : Q1 2024 revenue. Q1 2024 revenue Quarterly activity Revenue: €194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was temporarily impacted by the reform of the supply of contrast products in France Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 April 2024, 5.45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical...

April 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch